Search clinical trials for: Dopamine D2 Receptor

Total 21767 results

Cancer Institute and Hospital, Chinese Academy...

Unknown

A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.

Gastric Cancer

China
Shaheed Zulfiqar Ali Bhutto Medical University

Completed

Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke

Aspiration Pneumonia | Acute Stroke

Pakistan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia

Schizophrenia
Wenhu Liu
Beijing Municipal Science & Technology Commission

Unknown

Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition

Vitamin D Deficiency | Malnutrition

China
Harbin Medical University

Terminated

Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer (repeat)

Gastric Cancer

China
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

Schizophrenia

China
Janssen-Cilag Pty Ltd

Completed

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

Schizophrenia

Australia
Johnson & Johnson Pte Ltd

Completed

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (PREVAIL)

Schizophrenia

China, Taiwan, Malaysia, Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Schizophrenia

Taiwan, Japan, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

Schizophrenia
Huazhong University of Science and Technology

Unknown

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

Schizophrenia

China
Janssen Korea, Ltd., Korea

Completed

Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (PERFECT)

Schizophrenia

Korea, Republic of
Janssen-Cilag Turkey

Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Schizophrenia

Turkey
Janssen Pharmaceutical K.K.

Completed

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Schizophrenia
Janssen-Cilag Pty Ltd

Completed

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

Schizophrenia
University of Maryland, Baltimore

Withdrawn

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

Schizophrenia

United States
Janssen Korea, Ltd., Korea

Completed

Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (PASS)

Schizophrenia

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (Power)

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

Schizophrenia
Mayo Clinic

Completed

Assessment of Combined Bowel Preparation for Capsule Endoscopy Study (CEPREP)

Gastrointestinal Hemorrhage

United States
Duke University

Completed

Metoclopramide Versus Placebo for GJ Placement

Enteral Nutrition | Radiation Exposure

United States
Janssen-Cilag International NV

Completed

Paliperidone Palmitate Flexible Dosing in Schizophrenia (PALMFlexS)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Spain, Israel, Portugal, Turkey, Greece, Sweden, Belgium, Netherlands, Hungary, Denmark, Lithuania, Latvia, Croatia, Estonia, Austria, Switzerland
Pharmathen S.A.

Completed

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

Schizophrenia

Jordan
University of Alabama at Birmingham
Ortho-McNeil Janssen Scientific Affairs, LLC; American Foundation for Suicide...

Completed

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation (AFSP)

Suicidal Ideation | Major Depressive Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Schizophrenia

United States, India, Romania, Russian Federation, Ukraine
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Massachusetts General Hospital

Terminated

Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder

Pediatric Bipolar Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function

Schizophrenia | Renal Impairment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder

Bipolar Disorder | Mania | Affective Psychosis, Bipolar
Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
Seoul National University Hospital
Johnson & Johnson

Completed

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Schizophrenia

Korea, Republic of
Yale University

Withdrawn

Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

Posttraumatic Stress Disorder

United States
Chonbuk National University Hospital
Janssen Korea, Ltd., Korea

Completed

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

First Episode Psychosis

Korea, Republic of
Janssen Research & Development, LLC

Completed

An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia

Schizophrenia

China
University of South Florida
Indiana University; Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

United States
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Dose Proportionality of Extended Release Paliperidone

Schizophrenia

3

Subscribe